Pavel Nikitin

Pavel Nikitin currently serves as an Advisor for the Strategic AI Program at Ashland University and is the Founder of Pine Consulting, specializing in antibody development projects utilizing both wet-lab and dry-lab methodologies. Previously, Pavel held the position of Senior Director of Antibody Engineering at Immunome, Inc., where significant achievements included the establishment of a therapeutic generation unit and integration of AI into antibody discovery, as well as preparing critical data that facilitated a strategic collaboration with AbbVie. Pavel's experience also encompasses roles as Senior Scientist at Bioverativ and True North Therapeutics, contributing to projects leading to acquisitions by Sanofi and investigating the effects of sutimlimab on human B cells. Earlier in the career, Pavel was a Presidential Postdoctoral Fellow at Novartis Institutes for BioMedical Research, playing a key role in the development of an antiviral antibody cocktail. Pavel holds a PhD in Molecular Genetics and Microbiology from Duke University School of Medicine and a Diploma with Honors in Molecular Biology from Novosibirsk State University.